Stazi Filippo
UOS Week Cardiology, UOC Cardiology, San Giovanni Addolorata Hospital, Rome, Italy.
Eur Heart J Suppl. 2025 Apr 16;27(Suppl 3):iii150-iii152. doi: 10.1093/eurheartjsupp/suaf034. eCollection 2025 Mar.
In the last 10 years, leadless pacemaker (PM) therapy has moved beyond the experimental phase and has become an established therapeutic option. A substantial body of data are now available, even with medium-length follow-ups, suggesting that leadless PMs are associated with fewer infections and fewer overall complications, particularly in the long term, compared with transvenous PMs. The introduction of VDD(R) pacing and, more recently, DDD(R), has expanded the indication area of these devices to a significantly larger number of patients. High costs, limited experience with replacement and the lack of randomized studies still limit their widespread adoption. However, for many patients, the leadless PM already represents the first therapeutic choice.
在过去10年中，无导线起搏器（PM）治疗已走出实验阶段，成为一种既定的治疗选择。即使是中期随访，现在也有大量数据表明，与经静脉起搏器相比，无导线起搏器感染更少，总体并发症更少，尤其是从长期来看。VDD（R）起搏以及最近的DDD（R）起搏的引入，将这些设备的适应症范围扩大到了更多患者。高成本、更换经验有限以及缺乏随机研究仍然限制了它们的广泛应用。然而，对于许多患者来说，无导线起搏器已经成为首选治疗方式。
